Wave Life Sciences up on FDA's rare pediatric disease tag for muscular disorder therapy

Wave Life Sciences

12/08/2024 14:18

** Shares of drug developer Wave Life Sciences  WVE.O  rise
4.6% to $5.66 premarket  
    ** Co says the U.S. FDA has granted the Rare Pediatric
Disease tag to its experimental therapy for the treatment of
certain patients with Duchenne muscular dystrophy (DMD)
    ** DMD is a genetic disorder, predominantly affecting boys,
characterized by progressive muscle degeneration and weakness
due to the alterations of a protein called dystrophin that helps
keep muscle cells intact
    ** The therapy, WVE-N531, is being tested in a potential
registrational trial and WVE expects to deliver data in Q3 2024
    ** FDA grants RPD designation to drugs that treat certain
serious or life-threatening diseases that primarily affect
children and fewer than 200,000 people in the United States
    ** Up to last close, stock up ~7% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))